Mandate

Vinge advises Flower in connection with the acquisition of the Pajkölen battery storage project

Vinge has advised the energy technology company Flower Infrastructure Technologies AB (“Flower”) in the acquisition of one of Sweden's largest battery storage projects, Pajkölen, from Arise AB (publ) (“Arise”). The project, which is a 40 MW / 80 MWh Ready-to-Build battery energy storage system (BESS), is located in the Kölvallen wind farm in Ljusdal municipality. The transaction comprise all shares in Pajkölen BESS AB, which owns all rights to the project.

Closing is subject to e.g. certain regulatory approvals and is expected to take place in the fourth quarter of 2024, with grid connection expected to be completed in the first half of 2025.

Through the acquisition, Flower strengthens its position as the country's leading actor in battery optimisation. Once the project is operational, Flower will have complete control over the entire battery value chain, opening up important revenue streams for renewable energy actors, such as grid operators or owners of renewable power.

Vinge's team consisted mainly of Peter Sundgren, Niklas Suni and Gustav Wahlberg (M&A), Kristoffer Larson (Real Estate and Construction), Lina Österberg (Environment), Carla Zachariasson and Ian Linde (Commercial Agreements) and Daniel Wendelsson, Dagne Sabockis and Alva Chambert (FDI).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025